1-13 of 13
Luc Friboulet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4943–4956.
https://doi.org/10.1158/1078-0432.CCR-24-1834
Published: 01 November 2024
View article titled, Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies
Open the PDF for Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies in another window
Includes: Supplementary data
Journal Articles

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini, Aleksandra Markovets, Lucy Ireland, Daniel O’Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J. Martin, Ludovic Bigot, Luc Friboulet, Ryan Hartmaier, Maria E. Cuomo, Simon T. Barry, Paul D. Smith, Nicolas Floc’h
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4143–4154.
https://doi.org/10.1158/1078-0432.CCR-23-2540
Published: 13 September 2024
View article titled, Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Open the PDF for Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations in another window
Includes: Supplementary data
Journal Articles

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

Naoual Menssouri, Loïc Poiraudeau, Carole Helissey, Ludovic Bigot, Jonathan Sabio, Tony Ibrahim, Cédric Pobel, Claudio Nicotra, Maud Ngo-Camus, Ludovic Lacroix, Etienne Rouleau, Lambros Tselikas, Anne Chauchereau, Félix Blanc-Durand, Alice Bernard-Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Emeline Colomba, Alina Fuerea, Laurence Albiges, Pernelle Lavaud, Paul van de Wiel, Eveline den Biezen, Yvonne Wesseling-Rozendaal, Santiago Ponce, Stefan Michiels, Christophe Massard, Daniel Gautheret, Fabrice Barlesi, Fabrice André, Benjamin Besse, Jean-Yves Scoazec, Luc Friboulet, Karim Fizazi, Yohann Loriot
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4504–4517.
https://doi.org/10.1158/1078-0432.CCR-22-3736
Published: 01 November 2023
View article titled, Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Open the PDF for Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Aït Oukhatar, Natalie Hoog-Labouret, Frank de Kievit, Karen Howarth, Clive Morris, Emma Green, Luc Friboulet, Sylvie Chabaud, Jean-François Guichou, Maurice Perol, Benjamin Besse, Jean-Yves Blay, Pierre Saintigny, David Planchard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6242–6253.
https://doi.org/10.1158/1078-0432.CCR-20-1037
Published: 01 December 2020
View article titled, Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <em>BRAF</em>-Mutant Metastatic Non–Small Cell Lung Cancer
Open the PDF for Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <em>BRAF</em>-Mutant Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 764–774.
https://doi.org/10.1158/1078-0432.CCR-19-2035
Published: 14 February 2020
View article titled, Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Open the PDF for Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olaussen, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 242–255.
https://doi.org/10.1158/1078-0432.CCR-19-1104
Published: 03 January 2020
View article titled, Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Open the PDF for Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Laura Mezquita, Mélanie Laporte, Aurélie Honoré, Yann Lecluse, Pauline Queffelec, Maud NgoCamus, Claudio Nicotra, Jordi Remon, Ludovic Lacroix, David Planchard, Luc Friboulet, Benjamin Besse, Françoise Farace
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6671–6682.
https://doi.org/10.1158/1078-0432.CCR-19-1176
Published: 15 November 2019
View article titled, Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <em>ALK</em>-Rearranged Non–Small-Cell Lung Cancer
Open the PDF for Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <em>ALK</em>-Rearranged Non–Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue

Luc Friboulet, Jean-Charles Soria, Ken André Olaussen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2369–2371.
https://doi.org/10.1158/1078-0432.CCR-18-4123
Published: 15 April 2019
View article titled, The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue
Open the PDF for The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue in another window
Journal Articles

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon, Jean-Yves Scoazec, Fabrice André, Jean-Charles Soria, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 5983–5991.
https://doi.org/10.1158/1078-0432.CCR-16-0917
Published: 15 December 2016
View article titled, Crizotinib-Resistant <em>ROS1</em> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <em>ROS1</em>- and <em>ALK</em>-Rearranged Lung Cancers
Open the PDF for Crizotinib-Resistant <em>ROS1</em> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <em>ROS1</em>- and <em>ALK</em>-Rearranged Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2745–2752.
https://doi.org/10.1158/1078-0432.CCR-14-3009
Published: 14 June 2015
View article titled, Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Open the PDF for Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib in another window
Includes: Supplementary data
Journal Articles

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 166–174.
https://doi.org/10.1158/1078-0432.CCR-14-1385
Published: 05 January 2015
View article titled, Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Open the PDF for Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View article titled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

Luc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, Ken André Olaussen, Stephan Vagner, Julien Adam, Aïcha Goubar, Nicolas Dorvault, Vladimir Lazar, Bastien Job, Benjamin Besse, Pierre Validire, Philippe Girard, Ludovic Lacroix, Johanna Hasmats, Fabienne Dufour, Fabrice André, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5562–5572.
https://doi.org/10.1158/1078-0432.CCR-11-0790
Published: 01 September 2011
View article titled, Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
Open the PDF for Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC in another window
Includes: Supplementary data